Anonymous
Guest
Anonymous
Guest
Feb 04, 2011 - CNBC
INDIANAPOLIS - Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
The maker of the antipsychotic Zyprexa and the antidepressant Cymbalta gave Lechleiter, 57, a salary of $1.5 million, according to a proxy statement filed Friday afternoon with the Securities and Exchange Commission.
He also received a performance-based cash bonus of $3 million, down 16 percent from 2009. A company spokesman said the bonus is based on the company's sales and earnings-per-share performance compared to a peer group, and Lilly exceeded that group by a higher margin in 2009 than it did last year.
Lechleiter received equity awards valued at about $8.2 million last year, down 27 percent from a total of nearly $11.3 million in 2009.
http://www.cnbc.com/id/41432541/Eli_Lilly_CEO_Lechleiter_sees_2010_pay_fall_22_pct
INDIANAPOLIS - Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
The maker of the antipsychotic Zyprexa and the antidepressant Cymbalta gave Lechleiter, 57, a salary of $1.5 million, according to a proxy statement filed Friday afternoon with the Securities and Exchange Commission.
He also received a performance-based cash bonus of $3 million, down 16 percent from 2009. A company spokesman said the bonus is based on the company's sales and earnings-per-share performance compared to a peer group, and Lilly exceeded that group by a higher margin in 2009 than it did last year.
Lechleiter received equity awards valued at about $8.2 million last year, down 27 percent from a total of nearly $11.3 million in 2009.
http://www.cnbc.com/id/41432541/Eli_Lilly_CEO_Lechleiter_sees_2010_pay_fall_22_pct